<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Florence</forename><surname>Pache</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hanna</forename><surname>Zimmermann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janine</forename><surname>Mikolajczak</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sophie</forename><surname>Schumacher</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Lacheta</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frederike</forename><forename type="middle">C</forename><surname>Oertel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Judith</forename><surname>Bellmann-Strobl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max Delbrück Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sven</forename><surname>Jarius</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory">Molecular Neuroimmunology Group</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brigitte</forename><surname>Wildemann</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory">Molecular Neuroimmunology Group</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Reindl</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Clinical Department of Neurology</orgName>
								<orgName type="institution">Medical University of Innsbruck</orgName>
								<address>
									<settlement>Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amy</forename><surname>Waldman</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Division of Neurology</orgName>
								<orgName type="institution">Children&apos;s Hospital of Philadelphia</orgName>
								<address>
									<region>Pennsylvania</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kerstin</forename><surname>Soelberg</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Vejle Hospital</orgName>
								<address>
									<settlement>Vejle</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Neurobiology</orgName>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Institute of Molecular Medicine</orgName>
								<orgName type="institution">University of Southern Denmark</orgName>
								<address>
									<settlement>Odense</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nasrin</forename><surname>Asgari</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Vejle Hospital</orgName>
								<address>
									<settlement>Vejle</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Department of Neurobiology</orgName>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Institute of Molecular Medicine</orgName>
								<orgName type="institution">University of Southern Denmark</orgName>
								<address>
									<settlement>Odense</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marius</forename><surname>Ringelstein</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Heinrich Heine University</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Orhan</forename><surname>Aktas</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Heinrich Heine University</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nikolai</forename><surname>Gross</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Ophthalmology, Medical Faculty</orgName>
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mathias</forename><surname>Buttmann</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Ach</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Ophthalmology</orgName>
								<orgName type="institution">University of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klemens</forename><surname>Ruprecht</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Friedemann</forename><surname>Paul</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max Delbrück Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Alexander</forename><forename type="middle">U</forename><surname>Brandt</surname></persName>
							<email>alexander.brandt@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">NeuroCure Clinical Research Center (NCRC)</orgName>
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">6515585893C128B70878C48B0E4A9975</idno>
					<idno type="DOI">10.1186/s12974-016-0720-6</idno>
					<note type="submission">Received: 1 April 2016 Accepted: 9 September 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:09+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been reported in patients with aquaporin-4 antibody (AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD).</s><s>The objective of this study was to describe optic neuritis (ON)-induced neuro-axonal damage in the retina of MOG-IgG-positive patients in comparison with AQP4-IgG-positive NMOSD patients.</s></p><p><s>Methods: Afferent visual system damage following ON was bilaterally assessed in 16 MOG-IgG-positive patients with a history of ON and compared with that in 16 AQP4-IgG-positive NMOSD patients.</s><s>In addition, 16 healthy controls matched for age, sex, and disease duration were analyzed.</s><s>Study data included ON history, retinal optical coherence tomography, visual acuity, and visual evoked potentials.</s><s>Results: Eight MOG-IgG-positive patients had a previous diagnosis of AQP4-IgG-negative NMOSD with ON and myelitis, and eight of (mainly recurrent) ON.</s><s>Twenty-nine of the 32 eyes of the MOG-IgG-positive patients had been affected by at least one episode of ON.</s><s>Peripapillary retinal nerve fiber layer thickness (pRNFL) and ganglion cell and inner plexiform layer volume (GCIP) were significantly reduced in ON eyes of MOG-IgG-positive patients (pRNFL = 59 ± 23 μm; GCIP = 1.50 ± 0.34 mm 3 ) compared with healthy controls (pRNFL = 99 ± 6 μm, p &lt; 0.001; GCIP = 1.97 ± 0.11 mm 3 , p &lt; 0.001).</s><s>Visual acuity was impaired in eyes after ON in MOG-IgG-positive patients (0.35 ± 0.88 logMAR).</s><s>There were no significant differences in any structural or functional visual parameters between MOG-IgGpositive and AQP4-IgG-positive patients (pRNFL: 59 ± 21 μm; GCIP: 1.41 ± 0.27 mm 3 ; Visual acuity = 0.72 ± 1.09 logMAR).</s><s>Importantly, MOG-IgG-positive patients had a significantly higher annual ON relapse rate than AQP4-IgGpositive patients (median 0.69 vs. 0.29 attacks/year, p = 0.004), meaning that on average a single ON episode caused less damage in MOG-IgG-positive than in AQP4-IgG-positive patients.</s><s>pRNFL and GCIP loss correlated with the number of ON episodes in MOG-IgG-positive patients (p &lt; 0.001), but not in AQP4-IgG-positive patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>(Continued from previous page)</head><p><s>Conclusions: Retinal neuro-axonal damage and visual impairment after ON in MOG-IgG-positive patients are as severe as in AQP4-IgG-positive NMOSD patients.</s><s>In MOG-IgG-positive patients, damage accrual may be driven by higher relapse rates, whereas AQP4-IgG-positive patients showed fewer but more severe episodes of ON.</s><s>Given the marked damage in some of our MOG-IgG-positive patients, early diagnosis and timely initiation and close monitoring of immunosuppressive therapy are important.</s></p><p><s>Keywords: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG), aquaporin-4 antibodies (AQP4-IgG), NMO-IgG, neuromyelitis optica, Devic syndrome, neuromyelitis optica spectrum disorders (NMOSD), optic neuritis, optical coherence tomography, visual evoked potentials, visual acuity, retinal neuro-axonal damage</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Myelin oligodendrocyte glycoprotein (MOG) is expressed on the outer surface of oligodendrocytic myelin sheaths, representing approximately 0.05 % of all myelinconstituting proteins <ref type="bibr" target="#b0">[1]</ref>.</s><s>Antibodies against MOG (MOG-IgG) have been detected in a proportion of aquaporin-4 (AQP4)-IgG-seronegative patients with neuromyelitis optica spectrum disorder (NMOSD) phenotype <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>MOG-IgG have further been reported in children with acute and relapsing-remitting inflammatory demyelinating encephalomyelitis as well as in a proportion of adults with inflammatory demyelinating diseases such as optic neuritis (ON) <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>.</s></p><p><s>Currently it is debated whether MOG-IgG-associated encephalomyelitis should be classified as an NMOSD subtype or as a separate disease entity <ref type="bibr" target="#b9">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr" target="#b10">[12]</ref>.</s><s>MOG-IgG-seropositive patients from NMOSD cohorts can show clinical features of recurrent transverse myelitis and ON, similar to AQP4-IgG-seropositive patients <ref type="bibr" target="#b3">[4]</ref>.</s><s>However, the cellular target of AQP4-IgG is an astrocytic water channel, suggesting a different mechanism of injury from MOG-IgG.</s><s>This is supported by a recent case study of a MOG-IgG-seropositive patient who showed severe demyelination with no evidence of astrocytopathy <ref type="bibr" target="#b11">[13]</ref> and by further brain biopsy case studies <ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref><ref type="bibr" target="#b14">[16]</ref>.</s></p><p><s>ON in NMOSD patients is often severe with marked retinal nerve fiber layer and ganglion cell layer loss, severe visual impairment including blindness, and a high frequency of bilateral events <ref type="bibr" target="#b15">[17,</ref><ref type="bibr" target="#b16">18]</ref>.</s><s>In around 20 % of affected eyes, macular microcysts are found in the inner nuclear layer as a sign of severe ON-related retinal injury <ref type="bibr" target="#b17">[19,</ref><ref type="bibr" target="#b18">20]</ref>.</s><s>In comparison, the extent of afferent visual system damage following ON in MOG-IgG-seropositive patients is less well understood.</s><s>Some previous studies, employing either structural or clinical assessment of visual function, suggested that MOG-IgG-positive patients have fewer attacks, better recovery from relapses, and less neuro-axonal retinal damage than AQP4-IgG-positive patients <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b19">21,</ref><ref type="bibr" target="#b20">22]</ref>.</s><s>However, it is a potential drawback that observation periods were relatively short and sample sizes low in those studies.</s><s>Moreover, some included mostly or exclusively Asian patients <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b20">22]</ref>; this could be relevant in that genetic factors have been proposed to play a role in NMOSD pathogenesis <ref type="bibr" target="#b15">[17]</ref>.</s><s>By contrast, more recent studies by others <ref type="bibr" target="#b21">[23,</ref><ref type="bibr" target="#b22">24]</ref> and us <ref type="bibr" target="#b23">[25]</ref> demonstrate that the disease follows a relapsing course in the long run in most MOG-IgG-positive patients.</s></p><p><s>The objective of this retrospective multicenter study was to investigate visual system damage after ON in a larger cohort of Caucasian patients with MOG-IgGassociated encephalomyelitis and long-term follow-up using a comprehensive assessment of the afferent visual system including structural, functional, and clinical parameters, and to compare it with that in AQP4-IgGpositive NMOSD patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Patients MOG-IgG-seropositive patients with a history of ON and available optical coherence tomography (OCT) data were recruited from a large retrospective study <ref type="bibr" target="#b23">[25,</ref><ref type="bibr" target="#b24">26]</ref>.</s><s>Sixteen patients (15 female; mean age 44.0 ± 15.2 years) were enrolled from six university hospitals in Europe (Germany: Berlin, Freiburg, Düsseldorf, Heidelberg, Würzburg; Denmark: Vejle).</s><s>The inclusion criteria were age ≥18 years, a confirmed history of ON (more than 3 months prior to visual assessments), and seropositivity for MOG-IgG.</s><s>A MOG-antibody serum titer of ≥1: 160 was classified as positive <ref type="bibr" target="#b24">[26]</ref>.</s><s>Clinical and paraclinical data on disease onset, relapse history, expanded disability status scale (EDSS) <ref type="bibr" target="#b25">[27]</ref>, visual acuity, OCT, magnetic resonance imaging (MRI), and immunotherapy were retrospectively collected.. Annualized relapse rate was calculated as the ratio of number of attacks and years since disease onset, excluding patients with disease duration of less than 1 year.</s><s>All patients were of Caucasian descent; all MOG-IgG-positive patients tested seronegative for AQP4-IgG, and vice versa (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Eight (50 %) MOG-IgG-positive patients had a previous diagnosis of-mainly recurrent-ON, and eight (50 %) had been diagnosed with NMOSD based on the clinical symptoms of ON and myelitis before anti-MOG-IgG was tested.</s><s>AQP4-IgG-positive NMOSD patients <ref type="bibr" target="#b26">[28]</ref> (n = 16, all female, mean age 43.2 ± 13.9 years) and healthy controls (HC, n = 16, 15 female, mean age 43.9 ± 15.4 years) were randomly selected from the research database of the NeuroCure Clinical Research Center (Charité -Universitätsmedizin Berlin, Berlin, Germany), matched for sex and age on cohort basis.</s><s>Two MOG-IgGpositive patients had co-occurring ophthalmologic conditions in both eyes: one had early-stage dry macular degeneration, and glaucoma was suspected in the other patient.</s><s>These two patients and their matched AQP4-IgG-positive patients and HC were included in the case descriptions but excluded from statistical analyses of OCT and visual function parameters.</s><s>Furthermore, only eyes with a previous ON were included in statistical analyses.</s><s>The local ethics committees approved the study protocol in accordance with the Declaration of Helsinki (1964) in its currently applicable version.</s><s>All participants provided informed written consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MOG-IgG and AQP4-IgG assay</head><p><s>MOG-IgG antibodies were detected using a live cellbased assay and a fixed cell-based assay, both employing HEK293 cells transfected with human full-length MOG; mock-transfected cells were used as control substrates (see part 1 for details <ref type="bibr" target="#b24">[26]</ref>).</s><s>AQP4-IgG were detected using a commercially available cell-based assay (EUROIMMUN, Lübeck, Germany) <ref type="bibr" target="#b27">[29,</ref><ref type="bibr" target="#b28">30]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Optical coherence tomography</head><p><s>OCT was performed using the Spectralis SD-OCT device (Heidelberg Engineering, Heidelberg, Germany) with the automatic real time function for image averaging.</s></p><p><s>Peripapillary retinal nerve fiber layer thickness (pRNFL) was derived from a standard ring scan around the optic nerve head (12°, 768 or 1536 A-scans, 16≤ART≤100).</s><s>A macular volume scan (25°× 30°, 61 vertical or horizontal B-scans, 768 A-scans per B-scan, 9≤ART≤15) was acquired for retinal layer analysis.</s><s>All scans underwent quality control <ref type="bibr" target="#b29">[31]</ref> and post-processing by one experienced rater in a standardized manner.</s><s>Layer segmentation was performed with the device's software (Eye Explorer 1.9.10.0 with viewing module 6.0.9.0).</s><s>Automatic segmentation results were carefully checked for errors and corrected if necessary by an experienced rater masked for the diagnosis of the subjects.</s><s>Combined ganglion cell and inner plexiform layer volume (GCIP), inner nuclear layer volume, and outer retinal layers volume including the outer plexiform and nuclear layer, inner and outer photoreceptor segments, and retinal pigment epithelium, were extracted from a 6-mm-diameter cylinder around the fovea <ref type="bibr" target="#b30">[32]</ref>.</s><s>Furthermore, all scans were examined for macular microcysts <ref type="bibr" target="#b17">[19]</ref> and other retinal pathologies.</s><s>The OCT parameters are visualized in Fig. <ref type="figure" target="#fig_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Visual function testing</head><p><s>Visual function testing was performed in MOG-IgGpositive and AQP4-IgG-positive patients at the same visit as OCT, except for one patient (see Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>).</s><s>Visual evoked potentials (VEP) were recorded with checkerboard stimulation (1°) with the device routinely used at the sites.</s><s>P100 peak latency was included in analysis and considered as abnormal when higher than 112 ms <ref type="bibr" target="#b31">[33]</ref> or when no clear signal could be evoked.</s><s>Habitually corrected visual acuity was tested with letter charts obtained as part of routine clinical care Early stage dry macular degeneration in both eyes and suspect for early stage glaucoma, respectively p-values in bold emphasis depict significant values (p &lt; 0.05) and converted into logMAR units.</s><s>A visual acuity of 0.2 logMAR and worse was considered abnormal.</s><s>When no letter could be recognized by the patient, visual acuity was registered with 2.0 logMAR for finger counting and 3.0 logMAR for hand motion recognition <ref type="bibr" target="#b32">[34]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis</head><p><s>Statistics were performed in R version 3.1.2</s><s><ref type="bibr" target="#b33">[35]</ref> using the packages psych, MASS, geepack and ggplot.</s><s>Differences in demographics between the cohorts were tested with Pearson chi-square test and non-parametric tests (Mann-Whitney U for two cohorts and Kruskal-Wallis for three cohorts).</s><s>Comparisons of visual system data between cohorts were performed using generalized estimating equation (GEE) models accounting for intrasubject inter-eye dependencies.</s><s>GEE results are provided with regression coefficient (B) and standard error (SE).</s><s>To investigate the extent of damage caused by subsequent ON episodes we employed a linear spline regression model as proposed by Ratchford et al. <ref type="bibr" target="#b35">[36]</ref>.</s><s>Due to the exploratory nature of this study, no correction for multiple comparisons was performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>The demographic and clinical features of MOG-IgGpositive patients are presented in Table <ref type="table" target="#tab_0">1</ref> and case-bycase clinical details are provided in Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>.</s><s>One patient had pediatric onset of the disease, Here, the defined layers are the RNFL, the ganglion cell and inner plexiform layer (GCIP), then INL and the outer retinal layers (ORL).</s><s>Macular microcysts can be seen as small black dots in the INL at 6 years of age; her case has been reported in an earlier publication <ref type="bibr">[11]</ref>.</s><s>All other patients had adult onset.</s><s>All MOG-IgG-positive patients had experienced at least one episode of ON (median 4.5, range 1-13) and, except for one with a short follow-up period (8 months, patient 8), presented with an unequivocally relapsing disease course.</s><s>Age at onset and disease duration at the time of examination did not differ between MOG-IgG-positive and AQP4-IgG-positive patients (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Detailed case studies, including therapy, are provided in parts 2 and 3 of this series of articles <ref type="bibr" target="#b23">[25,</ref><ref type="bibr" target="#b36">37]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OCT and visual function in MOG-IgG-positive ON</head><p><s>Two eyes from two patients had to be excluded from the analysis owing to acute ON at the time of assessment.</s><s>Thus, 23 eyes from 14 MOG-IgG-positive patients were analyzed at a median time of 16.4 months (range 3-125 months) since the most recent episode of ON.</s><s>Detailed afferent visual system parameters of all patients are given in Table <ref type="table" target="#tab_1">2</ref>, and case-by-case descriptions are provided in Additional file 2: Table <ref type="table" target="#tab_1">S2</ref>.</s></p><p><s>Reduced pRNFL thickness compared with the manufacturer's normative data was found in 18 of the 23 (78.2 %) ON-affected eyes of the MOG-IgG-positive group (mean 59 ± 23 μm).</s><s>In addition, two fellow eyes without clinically evident previous ON and with normal VEPs showed reduced RNFL thickness (51 μm and 75 μm, respectively).</s><s>Five ON eyes (21.7 %) but none of the non-ON eyes had macular microcysts in the inner nuclear layer.</s><s>Of 20 ON eyes with available VEP data, 12 (60 %) eyes had abnormal P100 latencies-two (10 %) of them despite normal pRNFL-while all four non-ON fellow eyes had normal VEPs.</s><s>Visual acuity was on average reduced in ON eyes (mean 0.35 ± 0.88 logMAR), with three eyes being legally blind at a visual acuity of 1.0 logMAR and worse.</s><s>On the other hand, 16 of 23 ON eyes (70 %) preserved visual acuity of 0.1 logMAR or better.</s></p><p><s>There were no significant differences in OCT and visual function measurements between MOG-IgG-positive patients with a history of both ON and myelitis (n = 8) and MOG-IgG-positive patients with a history only of recurrent ON (n = 8) (not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison with HC and AQP4-IgG-positive NMOSD patients</head><p><s>We then compared the afferent visual system damage in ON eyes of MOG-IgG-positive patients with age-and sex-matched HC and with ON eyes of AQP4-IgGpositive NMOSD patients (Table <ref type="table" target="#tab_1">2</ref>, Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>As expected, pRNFL and GCIP were significantly lower than in HC both in the MOG-IgG-positive group (both p &lt; 0.001) and in the AQP4-IgG-positive group (both p &lt; 0.001).</s><s>Furthermore, inner nuclear layer volume was significantly greater than HC in the MOG-IgG-positive subgroup (p = 0.009), but not in the AQP4-IgG-positive NMOSD subgroup.</s><s>By contrast, no significant difference was noted between MOG-IgG-positive and AQP4-IgGpositive patients regarding retinal layer measures.</s><s>Macular  <ref type="table" target="#tab_1">2</ref>).</s><s>Visual acuity was less impaired in the MOG-IgG-positive subgroup (mean 0.35 ± 0.88 logMAR) than in the AQP4-IgG-positive subgroup (0.72 ± 1.09); however, the difference was not significant (p = 0.30).</s></p><p><s>Of note, the MOG-IgG-positive patients showed a significantly higher annualized relapse rate both for all relapses and-even higher-for ON than the AQP4-IgGpositive patients (p = 0.026 and p = 0.004, respectively), despite similar disease duration (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Retinal damage and number of ON episodes</head><p><s>In MOG-IgG-positive patients, a higher number of ON episodes was associated with more severe pRNFL and GCIP loss (GEE: pRNFL B = −4.9,</s><s>SE = 1.40, p &lt; 0.001; GCIP B = −0.07,</s><s>SE = 0.02, p &lt; 0.001), but not with changes of the inner nuclear layer or outer retinal layers.</s><s>By contrast, in AQP4-IgG-positive patients the extent of retinal layer changes did not correlate with the number of ON attacks.</s></p><p><s>In our cross-sectional data, the first ON episode caused a mean pRNFL loss of 12.8 μm (p = 0.001) in MOG-IgG-positive patients and 32.8 μm (p &lt; 0.001) in AQP4-IgG-positive patients in comparison with HC eyes.</s><s>In contrast, a second episode of ON caused additional pRNFL loss of 37.8 μm (p &lt; 0.001) in MOG-IgGpositive patients and 20.8 μm in AQP4-IgG-positive patients, although that difference was not significant (p = 0.07) (Fig. <ref type="figure">3</ref>).</s><s>A similar association was found for GCIP volume (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This study shows that ON in MOG-IgG-positive patients leads to severe pRNFL and GCIP thinning and visual function impairment, the extent of which is comparable to ON in patients with AQP4-IgG.</s><s>Moreover, it suggests that the damage accrual may be driven by higher relapse rates in MOG-IgG-positive patients, in contrast to more severe ON-associated damage during a single ON episode in AQP4-IgG-positive patients.</s></p><p><s>Some earlier studies of MOG-IgG-positive patients, which were characterized by relatively short observation periods, suggested that MOG-IgG-seropositive patients present more often with monophasic disease and have a milder clinical phenotype and better recovery than patients with AQP4-IgG-seropositive NMOSD <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b37">38]</ref>.</s><s>By contrast, all but one of our patients showed a relapsing disease course with a high frequency of attacks, protracted ON episodes, and, in some cases, severe visual impairment.</s><s>In line with our findings, two more recent studies have also demonstrated that MOG-IgG seropositivity is frequently associated with a recurrent disease course in patients with ON <ref type="bibr" target="#b21">[23,</ref><ref type="bibr" target="#b22">24]</ref>.</s><s>Concerning neuro-axonal damage of the retina, a recent study including 19 MOG-IgG-positive patients reported less retinal nerve fiber and ganglion cell layer damage than in AQP4-IgG-positive patients following ON <ref type="bibr" target="#b20">[22]</ref>.</s><s>As a limitation, however, that study included exclusively monophasic patients.</s><s>By contrast, in our study we demonstrated that retinal neuro-axonal damage after ON in MOG-IgG-positive patients is at least as severe as in AQP4-IgG-positive NMOSD patients, compared with our own control cohort as well as with previously published AQP4-IgG-positive cohorts <ref type="bibr" target="#b38">[39,</ref><ref type="bibr" target="#b39">40]</ref> when patients with long-term follow-up (mean ~7 years) and, accordingly, relapsing disease course are included in the analysis.</s></p><p><s>Notably, although average visual function was impaired in relapsing ON of both MOG-IgG-positive and AQP4-IgG-positive patients, some MOG-IgG-positive patients performed comparably well on high-contrast visual acuity testing despite severe neuro-axonal retinal damage: 70 % of ON eyes retained a visual acuity of 0.1 logMAR or better after ON.</s><s>However, visual acuity was obtained in non-standardized manner as high-contrast letter acuity in clinical routine; thus the reliance on functional testing may underestimate the actual extent of damage to the afferent visual system.</s><s>The impact of structural damage as demonstrated in the present study should be further investigated with low-contrast letter acuity, color vision testing, visual fields, and quality of life scales.</s></p><p><s>Our study features strengths and limitations.</s><s>Among its strengths we count the relatively high number of patients included, given the low prevalence of the disease, the fact that reliable assays for detecting antibodies to full-length human MOG have become available only relatively recently, and the fact that OCT is not yet routinely and generally available.</s><s>A further potential strength is that our cohort was genetically homogeneous with all patients and controls being of Caucasian origin.</s><s>As a potential limitation, not all patients were systematically tested for other optic neuropathies, such as Leber's hereditary optic neuropathy (LHON).</s><s>While a mitochondrial mutation may have contributed to the marked pRNFL thinning in the female patient with pediatric onset of disease (patient 4 in Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>), the time course (approximately 10 years before the contralateral eye demonstrated a mild decrease in visual acuity) is unusual for LHON, a condition which typically affects both eyes within months of each other without a relapsing and remitting course.</s><s>Finally, data were collected retrospectively in a multicenter approach.</s><s>As a result, additional data, e.g., the Multiple Sclerosis Function Composite or OCT scans obtained during acute optic neuritis, were not available.</s><s>Moreover, we were not able to systematically correlate optic nerve MRI <ref type="bibr" target="#b21">[23,</ref><ref type="bibr" target="#b40">41]</ref> and OCT in this study, Fig. <ref type="figure">3</ref> Retinal nerve fiber layer loss as a function of optic neuritis in MOG-IgG-positive and AQP4-IgG-positive patients.</s><s>Peripapillary retinal nerve fiber layer (pRNFL) loss caused by sequential episodes of optic neuritis (ON), estimated from cross-sectional data, in comparison with eyes without optic neuritis from the healthy control (HC) cohort.</s><s>(a) ON eyes from MOG-IgG-seropositive patients (MOG-IgG+); (b) ON eyes from AQP4-IgGseropositive patients (AQP4-IgG+).</s><s>P-values were computed with linear regressions which would require highly standardized MRI protocols and a prospective study design.</s><s>However, prospective studies as well as single-center studies in MOG-IgGpositive patients are difficult to perform due to the condition's rarity and the currently limited access to MOG-IgG testing.</s><s>Moreover, all patients with available data seen at the various centers were included in the analysis, thereby reducing the risk of referral bias.</s><s>Nonetheless, the preliminary evidence derived from this retrospective exploratory study needs to be confirmed in further prospective and independent studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In summary, we demonstrate (a) that a substantial proportion of MOG-IgG-seropositive patients develop retinal neuro-axonal damage; (b) that visual impairment and structural damage increase with the number of attacks and thus with disease duration; and, importantly, (c) that the extent of neuro-axonal damage in MOG-IgG-positive patients with ON is not different from that in patients with AQP4-IgG-positive ON in the long-term course of the disease, i.e., when patients with relapsing rather than monophasic ON are taken into account.</s><s>Given the marked structural and functional damage in some of our ON patients, early diagnosis, timely initiation of immunosuppressive therapy, and close monitoring of treatment efficacy seem paramount.</s><s>Although no systematic investigations of drugs for relapse prevention in this condition have yet been conducted, retrospective data on treatment responses (see part 2 of this series <ref type="bibr" target="#b23">[25]</ref>), as well as available evidence in favor of a pathogenic role of MOG-IgG <ref type="bibr" target="#b14">[16,</ref><ref type="bibr" target="#b28">30]</ref>, suggest that-in accordance with treatment recommendations for AQP4-IgG-positive NMOSD <ref type="bibr" target="#b41">[42]</ref>-patients with MOG-IgG-positive ON may benefit from high-dose intravenous methylprednisolone treatment and, possibly, plasma exchange for acute attacks as well as from immunosuppression for attack prevention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p><s>Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>.</s><s>Demographic, clinical and serological data.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Sample images from patient 1. a Sample images from a peripapillary ring scan.</s><s>On the left, a scanning laser ophthalmoscopy image shows scan positioning (in green).</s><s>On the right, an OCT scan shows severe peripapillary retinal nerve fiber layer (pRNFL) loss (between the inner limiting membrane [ILM], shown in red, and the lower border, in turquoise).</s><s>b Ring-scan data in comparison with normative device data from both eyes of this patient.</s><s>Black numbers display the thickness measurements (in μm) of the subject, green numbers the average thickness in the age-matched reference group.</s><s>Sectors are classified in comparison with the reference group: green, thickness values within the 5th and 95th percentile range; yellow, 1st to 5th percentile range; red, below the 1st percentile.</s><s>Abbreviations: G global, NS nasal-superior, N nasal, NI nasal-inferior, TI temporal-inferior, T temporal, TS temporal-superior.</s><s>c Macular scan of the same patient.</s><s>On the left, the dark, sickle-shaped area on and around the macula represents tissue with microcysts in the inner nuclear layer (INL).</s><s>The white circle indicates the 6-mm-diameter cylinder in which intraretinal layers are analyzed.</s><s>The green line with arrow shows the scanning position of the OCT scan on the right.</s><s>Here, the defined layers are the RNFL, the ganglion cell and inner plexiform layer (GCIP), then INL and the outer retinal layers (ORL).</s><s>Macular microcysts can be seen as small black dots in the INL</s></p></div></figDesc><graphic coords="4,155.89,94.82,283.48,341.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 Retinal layer measures of MOG-IgG-positive and AQP4-IgG-positive ON eyes.</s><s>Boxplots for the comparison of retinal layer measures of the eyes in the healthy control group and the ON eyes of MOG-IgG-positive (MOG-IgG+) and AQP4-IgG-positive (AQP4-IgG+) NMOSD patients.</s><s>(a) Peripapillary retinal nerve fiber layer thickness derived from a ring scan (pRNFL); (b-d) Intraretinal layer volumes quantified in a 6-mm-diameter cylinder around the fovea centralis: (b) ganglion cell and inner plexifom layer volume (GCIP); (c) inner nuclear layer volume (INL); (d) outer retinal layer volume comprising all layers from outer plexiform layer to Bruch's membrane</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Abbreviations AQP4-IgG: Aquaporin-4 immunoglobulin G; ARR: Annualized relapse rate; EDSS: Expanded disability status scale; GCIP: Ganglion cell and inner plexiform layer volume; GEE: Generalized estimating equation; LHON: Leber's hereditary optic neuropathy; MOG-IgG: Myelin oligodendrocyte glycoprotein antibody-seropositive patients; MWU: Wilcoxon-Mann-Whitney U test; OCT: Optical coherence tomography; ON: Optic neuritis; pRNFL: Peripapillary retinal nerve fiber layer thickness; SD: Standard deviation; SE: Standard error; VEP: Visual evoked potentials</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Demographic data</s></p></div></figDesc><table><row><cell>MOG-IgG</cell><cell>AQP4-IgG</cell><cell>MOG-IgG vs. AQP4-IgG (MWU/Chi 2 )</cell></row><row><cell></cell><cell></cell><cell>p</cell></row></table><note><p><s>Abbreviations: AQP4-IgG aquaporin-4 antibody-seropositive NMOSD patients, ARR annualized relapse rate, EDSS expanded disability status scale, f female, m male, MOG-IgG myelin oligodendrocyte glycoprotein antibody-seropositive patients, MWU Wilcoxon-Mann-Whitney U test, ON optic neuritis, SD standard deviation a)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Structural and functional data of MOG-IgG-positive patients' ON eyes in comparison to AQP4-IgG-positive patients and control data</s></p></div></figDesc><table><row><cell></cell><cell>MOG-IgG positive ON</cell><cell>AQP4-IgG positive ON</cell><cell>HC (n = 28 eyes from</cell><cell cols="3">MOG-IgG positive vs.</cell><cell cols="3">MOG-IgG positive</cell></row><row><cell></cell><cell>(n = 23 eyes from</cell><cell>(n = 21 eyes from</cell><cell>14 subjects)</cell><cell cols="3">AQP4-IgG positive (GEE)</cell><cell cols="2">vs. HC (GEE)</cell></row><row><cell></cell><cell>14 subjects)</cell><cell>14 subjects)</cell><cell></cell><cell>B</cell><cell>S E</cell><cell>p</cell><cell>B</cell><cell>S E</cell><cell>p</cell></row><row><cell>Retinal OCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Average pRNFL (μm)</cell><cell>59 ± 23</cell><cell>59 ± 21</cell><cell>99 ± 6</cell><cell>−0.6</cell><cell>7.58</cell><cell>0.94</cell><cell>39.0</cell><cell cols="2">6.01 &lt;0.001</cell></row><row><cell>Nasal pRNFL (μm)</cell><cell>44 ± 21</cell><cell>45 ± 24</cell><cell>74 ± 12</cell><cell>0.2</cell><cell>7.85</cell><cell>0.98</cell><cell>28.6</cell><cell cols="2">6.01 &lt;0.001</cell></row><row><cell>Temporal pRNFL (μm)</cell><cell>44 ± 16</cell><cell>40 ± 15</cell><cell>71 ± 10</cell><cell>−3.0</cell><cell>4.51</cell><cell>0.50</cell><cell>27.6</cell><cell cols="2">4.26 &lt;0.001</cell></row><row><cell>GCIP (mm 3 )</cell><cell>1.50 ± 0.34</cell><cell>1.41 ± 0.27</cell><cell>1.97 ± 0.11</cell><cell>−0.10</cell><cell>0.10</cell><cell>0.35</cell><cell>0.47</cell><cell cols="2">0.08 &lt;0.001</cell></row><row><cell>INL (mm 3 )</cell><cell>1.03 ± 0.10</cell><cell>1.01 ± 0.11</cell><cell>0.95 ± 0.04</cell><cell>−0.02</cell><cell>0.04</cell><cell>0.55</cell><cell cols="3">−0.07 0.03 0.009</cell></row><row><cell>ORL (mm 3 )</cell><cell>4.86 ± 0.26</cell><cell>4.93 ± 0.26</cell><cell>4.73 ± 0.21</cell><cell>0.04</cell><cell>0.09</cell><cell>0.70</cell><cell cols="3">−0.13 0.09 0.14</cell></row><row><cell>Eyes with macular</cell><cell>5 (21.7 %)</cell><cell>4 (19.0 %)</cell><cell></cell><cell>Chi 2</cell><cell></cell><cell>&gt;0.99</cell><cell></cell><cell></cell></row><row><cell>microcysts (n)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Visual function</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Visual acuity/logMAR</cell><cell>0.35 ± 0.88</cell><cell>0.72 ± 1.09</cell><cell>-</cell><cell>0.33</cell><cell>0.32</cell><cell>0.30</cell><cell></cell><cell></cell></row><row><cell cols="2">Abnormal P100 latency* 12 (57 %)</cell><cell>10 (50 %)</cell><cell>-</cell><cell>Chi 2</cell><cell></cell><cell>0.88</cell><cell></cell><cell></cell></row></table><note><p><s>OCT and visual function results are not including data from the two patients with early stage dry macular degeneration in both eyes and glaucoma, respectively, and their respective AQP4-IgG-positive controls and healthy controls.</s><s>Furthermore, two eyes of two MOG-IgG positive patients were excluded due to acute ON at time of examination.</s><s>Explanations: All data are given as mean ± standard deviation (minimummaximum), if not declared different AQP4-IgG aquaporin-4 antibody-seropositive NMOSD patients, GCIP ganglion cell and inner plexiform layer, HC healthy controls, INL inner nuclear layer, ON eyes with history of optic neuritis, MOG-IgG myelin oligodendrocyte glycoprotein antibody-seropositive patients, ORL outer retinal layers including layer from outer plexiform layer to Bruch's membrane, pRNFL peripapillary retinal nerve fiber layer p-values in bold emphasis depict significant values (p &lt; 0.05) * VEP data were available for 20 out of 23 ON eyes of MOG-IgG positive patients and 20 out of 21 eyes of AQP4-IgG positive patients microcysts were found in both subgroups in similar prevalence, but differences in microcyst size or extend might have led to a high variability of inner nuclear layer volume values (Table</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>This work was supported by the Dietmar Hopp Stiftung (BW), Merck Serono (BW), the German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis, FrP, KR and OA; N2-ADVISIMS, FrP and AB), the German Federal Ministry for Economic Affairs and Technology (EXIST-Forschungstransfer RETINEU, AB), the German Research Foundation (DFG EXC 257, FP), the Austrian Federal Ministry of Science, Research and Economy (grant Big Wig MS, MRe), the Eugene Devic European Network (EDEN) project (Eurpean Research Area-Net ERARE 2, MRe); the Austrian Science Fund (FWF project I916; MRe).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p><s>The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>FlP participated in the design of the study, acquired clinical information, and drafted the manuscript.</s><s>HZ performed OCT post-processing and statistical analysis and drafted the manuscript.</s><s>JM acquired OCT and visual function data.</s><s>SS, AL, and FCO.</s><s>acquired clinical and visual function data.</s><s>JBS participated in the design of the study and acquired clinical data.</s><s>MRe and SJ provided MOG-IgG results and contributed to interpretation of the data.</s><s>SJ and BW contributed OCT and clinical data and contributed to interpretation of the data.</s><s>AW contributed to interpretation of the data.</s><s>KS acquired OCT and visual function data.</s><s>NA acquired clinical data and contributed to interpretation of the data.</s><s>MRi acquired OCT, clinical, and visual function data.</s><s>OA acquired clinical data.</s><s>NG acquired OCT, clinical, and visual function data.</s><s>KR participated in the design of the study and contributed to interpretation of the data.</s><s>MB acquired clinical data, contributed to interpretation of the data, and edited the manuscript.</s><s>TA acquired OCT and visual function data.</s><s>FrP contributed to the interpretation of the data and drafted the manuscript.</s><s>AUB conceived the study and participated in its design and coordination contributed to analysis, and drafted the manuscript.</s><s>All authors were involved in revising the manuscript for intellectual content and read and approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>FlP has received a research grant from Novartis Pharmaceuticals and travel grants from Genzyme, a Sanofi company.</s><s>HZ has received speaking fees from Teva and Bayer.</s><s>JM has received speaking fees from Teva and Biogen Idec.</s><s>B.W. has received speaking/consultation honoraria and travel grants from Bayer Healthcare, Biogen Idec, Merck Serono, and Genzyme, a Sanofi company.</s><s>ATW has received support from the National Institutes of Health and Biogen Idec.</s><s>MRi has received speaker honoraria from Novartis and Bayer and travel reimbursements from Bayer Schering, Biogen Idec, and Genzyme.</s><s>OA has received advisor fees or honoraria from Bayer HealthCare, Biogen, Chugai, Genzyme, MedImmune, Novartis, and Teva; and research support from Bayer HealthCare, Biogen, Novartis, and Teva.</s><s>KR has received research support from Novartis as well as speaking fees or travel grants from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi/Genzyme, Teva, Roche, and Novartis.</s><s>FrP has received research grants and speaker honoraria from Bayer, Teva, Genzyme, Merck, Novartis, and MedImmune and is a member of the steering committee of the OCTIMS study (Novartis).</s><s>AUB. has received consulting fees from Biogen, Novartis, Teva, Nexus, and Motognosis and funding for research from Novartis and Biogen.</s><s>All other authors report nothing to disclose.</s><s>None of the reported disclosures interfered with the present study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p><s>All participants provided informed written consent for publication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p><s>The study was approved by the local ethics committees of the participating centers.</s><s>All participants provided informed written consent.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The spectrum of MOG autoantibody-associated demyelinating diseases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Reindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Pauli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rostásy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="455" to="461" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gredler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rostasy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Dujmovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pfaller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroinflammation</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">184</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica</title>
		<author>
			<persName><forename type="first">K</forename><surname>Rostásy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Hennes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gredler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guenther</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler J</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1052" to="1059" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Callegaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lana-Peixoto</forename></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Jorge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="474" to="481" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kitley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Murchison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>George</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="276" to="283" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain</title>
		<author>
			<persName><forename type="first">S</forename><surname>Saadoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Waters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vincent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Papadopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol Commun</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">35</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lechner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Hennes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="265" to="272" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation</title>
		<author>
			<persName><forename type="first">S-M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Woodhall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vincent</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608758/" />
		<imprint>
			<date type="published" when="2016-02-18">2016 Feb 18</date>
			<biblScope unit="volume">2</biblScope>
		</imprint>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Höftberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sepulveda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Armangue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rostásy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cobo</forename><surname>Calvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler J</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="866" to="874" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflammation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Zamvil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Slavin</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309525/" />
	</analytic>
	<monogr>
		<title level="j">Neurol Neuroimmunol Neuroinflammation</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<date type="published" when="2015-02-23">2015. 2015 Feb 23. 2015. 2015 Dec 16</date>
		</imprint>
	</monogr>
	<note>Reindl M, Rostasy K. MOG antibody-associated diseases. Internet</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice</title>
		<author>
			<persName><forename type="first">O</forename><surname>Aktas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page">243</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kiyota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kuroda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nishiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takahashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler J</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="656" to="659" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Histopathology and clinical course of MOG-antibody-associated encephalomyelitis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Spadaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Gerdes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ertl-Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Laurent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krumbholz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Clin Transl Neurol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="295" to="301" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Pauli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Höftberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Reindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Beer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rhomberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Neuroimmunol Neuroinflammation</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e175</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in &quot;pattern II multiple sclerosis&quot; and brain biopsy findings in a MOG-IgGpositive case</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Metz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>König</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paul</surname></persName>
		</author>
		<idno type="DOI">10.1177/1352458515622986</idno>
	</analytic>
	<monogr>
		<title level="j">Mult Scler J</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Neuromyelitis optica: clinical features, immunopathogenesis and treatment</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wildemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="149" to="164" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Seze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lana</forename><forename type="middle">-</forename><surname>Peixoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Palace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schippling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler J</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="678" to="688" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kaufhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Oberwahrenbrock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e71145</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">In vivo identification of morphologic retinal abnormalities in neuromyelitis optica</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Sotirchos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saidha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Byraiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Mealy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Sepah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="1406" to="1414" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Martinez-Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sepulveda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rostásy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="187" to="193" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Akaishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nakashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takeshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Doi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="446" to="448" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ramanathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Reddel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jde</forename><surname>Parratt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Barnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Gatt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Neuroimmunol Neuroinflammation</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">e40</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Chalmoukou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Alexopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Akrivou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stathopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Neuroimmunol Neuroinflammation</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e131</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kleiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Borisow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Asgari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pitarokoili</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12974-016-0718-0</idno>
	</analytic>
	<monogr>
		<title level="j">J Neuroinflammation</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kleiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Borisow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Asgari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pitarokoili</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12974-016-0717-1</idno>
	</analytic>
	<monogr>
		<title level="j">J Neuroinflammation</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Kurtzke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1444" to="1452" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">International consensus diagnostic criteria for neuromyelitis optica spectrum disorders</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Wingerchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Banwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cabre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chitnis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="177" to="189" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Probst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Borowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Franciotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wildemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Stoecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">291</biblScope>
			<biblScope unit="page" from="52" to="56" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Aquaporin-4 Antibodies (NMO-IgG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wildemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Pathol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="661" to="683" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tewarie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Balk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Costello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schippling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e34823</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Reliability of Intra-Retinal Layer Thickness Estimates</title>
		<author>
			<persName><forename type="first">T</forename><surname>Oberwahrenbrock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weinhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mikolajczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Beckers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0137316</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Pattern reversal evoked potentials: gender differences and age-related changes in amplitude and latency</title>
		<author>
			<persName><forename type="first">R</forename><surname>Emmerson-Hanover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Shearer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Creel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Dustman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Electroencephalogr Clin Neurophysiol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="93" to="101" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Proper method for calculating average visual acuity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Holladay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Refract Surg Thorofare NJ</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="388" to="391" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">R: a language and environment for statistical computing</title>
		<author>
			<persName><forename type="first">R</forename><surname>Development Core</surname></persName>
		</author>
		<author>
			<persName><surname>Team</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Austria: R Foundation for Statistical Computing</title>
		<ptr target="http://www.R-project.org" />
		<imprint>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ratchford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Quigg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Conger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Frohman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Frohman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Balcer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="302" to="308" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement -frequency, presentation and outcome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kleiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Asgari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pitarokoili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Borisow</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12974-016-0719-z</idno>
	</analytic>
	<monogr>
		<title level="j">J Neuroinflammation</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wildemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuempfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ringelstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Geis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroinflammation</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Oberwahrenbrock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kaufhold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Kadas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Petzold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e66151</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Seze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lana</forename><forename type="middle">-</forename><surname>Peixoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Palace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schippling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="678" to="688" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Acute optic neuritis. Neurol Neuroimmunol Neuroinflammation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Galetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Villoslada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shindler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Parr</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516397/" />
		<imprint>
			<date type="published" when="2015">2015. 2016 Jun 2</date>
			<biblScope unit="volume">2</biblScope>
		</imprint>
	</monogr>
	<note>Internet. cited</note>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<title level="m" type="main">Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group</title>
		<author>
			<persName><forename type="first">C</forename><surname>Trebst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berthele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schippling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wildemann</surname></persName>
		</author>
		<imprint>
			<publisher>NEMOS</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">261</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
